Search

Your search keyword '"Fanale, Michelle"' showing total 1,175 results
Start Over Author "Fanale, Michelle"
1,175 results on '"Fanale, Michelle"'

3. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, Park, Haeseong, Call, S Greg, Madwani, Kiran, Oki, Yasuhiro, Subbiah, Vivek, Hong, David S, Naing, Aung, Velez-Bravo, Vivianne M, Barnes, Tamara G, Hagemeister, Fredrick B, Falchook, Gerald S, Karp, Daniel D, Wheler, Jennifer J, Piha-Paul, Sarina A, Garrido-Laguna, Ignacio, Shpall, Elizabeth J, Fayad, Luis E, Neelapu, Sattva S, Meric-Bernstam, Funda, Kurzrock, Razelle, and Fanale, Michelle A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Rare Diseases, Transplantation, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Everolimus, Female, Hematopoietic Stem Cell Transplantation, Histone Deacetylase Inhibitors, Histone Deacetylases, Hodgkin Disease, Humans, Male, Middle Aged, Recurrence, Sirolimus, Stem Cell Transplantation, TOR Serine-Threonine Kinases, Vorinostat, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and methodsDuring the dose-escalation study (ClinicalTrials.gov number: NCT01087554) with the HDAC inhibitor vorinostat and the mTOR inhibitor sirolimus (V+S), a patient with Hodgkin lymphoma refractory to nine prior therapies demonstrated a partial response (PR) lasting for 18.5 months, which promoted additional enrollment of patients with Hodgkin lymphoma as well as exploration of an alternative combination of vorinostat and mTOR inhibitor everolimus (V+E).ResultsA total of 40 patients with refractory Hodgkin lymphoma received V+S (n = 22) or V+E (n = 18). Patients received a median of five prior therapies, including brentuximab (n = 39), autologous stem cell transplantation (n = 26), and allogeneic stem cell transplantation (n = 12). The most frequent grade ≥3 treatment-related adverse event was thrombocytopenia in 55% and 67% of patients treated with V+S and V+E, respectively. Complete response was reported in 6 (27%) patients treated with V+S and 2 (11%) patients treated with V+E, and PR was reported in 6 patients (27%) treated with V+S and 4 (22%) patients treated with V+E (objective response rate of 55% and 33%, respectively). In summary, combined HDAC and mTOR inhibition had encouraging activity in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma and warrants further investigation.ConclusionsCombined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation.

Published
2020

4. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.

Author

Kim, Jeong A, primary, Hahn, Uwe, additional, Kim, Won-Seog, additional, Fleury, Isabelle, additional, Laribi, Kamel, additional, Bergua Burgues, Juan Miguel, additional, Bouabdallah, Krimo, additional, Forward, Nick, additional, Bijou, Fontanet, additional, MacDonald, David, additional, Portell, Craig Anthony, additional, Ghesquieres, Hervé, additional, Nowakowski, Grzegorz S., additional, Yasenchak, Christopher A., additional, Rustia, Evelyn, additional, Fanale, Michelle, additional, Jie, Fei, additional, and Bartlett, Nancy L., additional

Published
2024
Full Text
View/download PDF

5. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Author

Savage, Kerry J., Horwitz, Steven M., Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O’Connor, Owen A., Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, and Iyer, Swaminathan

Published
2022
Full Text
View/download PDF

9. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.

Author

Brammer, Jonathan, Chihara, Dai, Poon, L, Caimi, Paolo, de Lima, Marcos, Ledesma, Celina, Rondon, Gabriela, Ciurea, Stefan, Nieto, Yago, Fanale, Michelle, Dabaja, Bouthaina, Maziarz, Richard, Champlin, Richard, Hosing, Chitra, and Oki, Yasuhiro

Subjects
Extranodal natural killer/T-cell lymphoma, SMILE, advanced stage, refractory disease, stem cell transplant, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Female, Humans, Lymphoma, Male, Middle Aged, Natural Killer T-Cells, Neoplasm Recurrence, Local, Prognosis, Stem Cell Transplantation, Young Adult
Abstract

BACKGROUND: Extra-Nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year. Patients with advanced stage III/IV ENKL and relapsed refractory ENKL have a poor prognosis even despite aggressive therapy and stem cell transplantation (SCT). We conducted a review of the management of 37 patients with advanced-stage and relapsed/refractory ENKL in a predominantly non-Asian cohort evaluating both chemotherapy and SCT outcomes. PATIENTS AND METHODS: We evaluated clinical outcomes in all patients treated for advanced stage III/IV or relapsed/refractory ENKL at MD Anderson cancer center between 2000-2014. Next, we collected stem cell transplant data from four transplant institutions to further evaluate outcomes of both allogeneic (allo-SCT) and autologous (auto-SCT) stem cell transplantation in ENKL. RESULTS: OS and PFS were 73% and 45% at one year, and 30% and 19% at 3-years, respectively. SMILE chemotherapy was more effective in maintaining a CR compared to CHOP (83% vs 17%). Only achievement of CR was prognostic for OS (HR 0.245, p=0.002) and PFS (HR 0.072, p) CONCLUSION: Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients.

Published
2018

11. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Author

Straus, David J, Długosz-Danecka, Monika, Connors, Joseph M, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Munoz, Javier, Lee, Hun Ju, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M, Younes, Anas, Gallamini, Andrea, Liu, Rachael, Little, Meredith, Fenton, Keenan, Fanale, Michelle, and Radford, John

Published
2021
Full Text
View/download PDF

12. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Author

Park, Haeseong, Garrido-Laguna, Ignacio, Naing, Aung, Fu, Siqing, Falchook, Gerald S, Piha-Paul, Sarina A, Wheler, Jennifer J, Hong, David S, Tsimberidou, Apostolia M, Subbiah, Vivek, Zinner, Ralph G, Kaseb, Ahmed O, Patel, Shreyaskumar, Fanale, Michelle A, Velez-Bravo, Vivianne M, Meric-Bernstam, Funda, Kurzrock, Razelle, and Janku, Filip

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Cancer, Hematology, Lymphoma, Orphan Drug, Clinical Research, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Histone Deacetylase Inhibitors, Humans, Hydroxamic Acids, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Sirolimus, TOR Serine-Threonine Kinases, Vorinostat, Young Adult, phase I, sirolimus, vorinostat, mTOR, HDAC, Oncology and carcinogenesis
Abstract

Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs) of combined mTOR inhibitor sirolimus (1 mg-5 mg PO daily) and HDAC inhibitor vorinostat (100 mg-400 mg PO daily) in patients with advanced cancer. Seventy patients were enrolled and 46 (66%) were evaluable for DLT assessment since they completed cycle 1 without dose modification unless they had DLT. DLTs comprised grade 4 thrombocytopenia (n = 6) and grade 3 mucositis (n = 1). Sirolimus 4 mg and vorinostat 300 mg was declared RP2D because MTD with sirolimus 5 mg caused significant thrombocytopenia. The grade 3 and 4 drug-related toxic effects (including DLTs) were thrombocytopenia (31%), neutropenia (8%), anemia (7%), fatigue (3%), mucositis (1%), diarrhea (1%), and hyperglycemia (1%). Of the 70 patients, 35 (50%) required dose interruption or modification and 61 were evaluable for response. Partial responses were observed in refractory Hodgkin lymphoma (-78%) and perivascular epithelioid tumor (-54%), and stable disease in hepatocellular carcinoma and fibromyxoid sarcoma. In conclusion, the combination of sirolimus and vorinostat was feasible, with thrombocytopenia as the main DLT. Preliminary anticancer activity was observed in patients with refractory Hodgkin lymphoma, perivascular epithelioid tumor, and hepatocellular carcinoma.

Published
2016

13. Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study.

Author

Evens, Andrew M, Yu, Kristina S, Liu, Nicholas, Surinach, Andy, Holmes, Katherine, Flores, Carlos, Fanale, Michelle A, Flora, Darcy R, and Parsons, Susan K

Abstract

Aim: To understand US physicians' frontline (1L) treatment preferences/decision-making for stage III/IV classic Hodgkin lymphoma (cHL). Materials & methods: Medical oncologists and/or hematologists (≥2 years' practice experience) who treat adults with stage III/IV cHL were surveyed online (October–November 2020). Results: Participants (n = 301) most commonly considered trial efficacy/safety data and national guidelines when selecting 1L cHL treatments. Most physicians (91%) rated overall survival (OS) as the most essential attribute when selecting 1L treatment. Variability was seen among regimen selection for hypothetical newly diagnosed patients, with OS cited as the most common reason for regimen selection. Conclusion: While treatment selection varied based on patient characteristics, US physicians consistently cited OS as the top factor considered when selecting a 1L treatment for cHL. Classic Hodgkin lymphoma (cHL) is a type of cancer that grows in lymph nodes. The researchers created a survey to assess how doctors in the USA choose medicine to treat patients who are newly diagnosed with an advanced stage of cHL (stage 3 or 4 out of 4 stages). We surveyed 301 doctors who treat patients with cHL. When choosing a medicine to treat cHL, most doctors said they consider results from research studies, how well the medicine works, information on the medicine's safety and recommendations in official guidelines. Most doctors said that overall survival (how long the patient survives after being diagnosed with cHL) is the most important outcome they consider when choosing a medicine to treat cHL. During the survey, doctors saw four unique patient profiles. These profiles differed in age, disease stage (how far along the cHL is) and other illnesses the patient has. While medicine choice was different across profiles, overall survival was still the reason for choosing each individual patient's medicine. These survey results show that doctors in the USA highly consider overall survival when choosing medicine for patients newly diagnosed with an advanced stage of cHL. Survey of US physicians who treat patients with #cHL shows that while frontline treatment selection varies based on individual characteristics of those with stage III/IV cHL, the regimen's reported overall survival is the top consideration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1

Author

Crosswell, Howland E., primary, LaCasce, Ann S., additional, Bartlett, Nancy L., additional, Straus, David J., additional, Savage, Kerry J., additional, Zinzani, Pier Luigi, additional, Collins, Graham P., additional, Fanale, Michelle, additional, Fenton, Keenan, additional, Dong, Cassie, additional, Miao, Harry, additional, and Grigg, Andrew P., additional

Published
2023
Full Text
View/download PDF

18. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B, Fayad, Luis, Romaguera, Jorge E, Fowler, Nathan, Fanale, Michelle A, Kwak, Larry W, Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J, Wierda, William, Fu, Kai, Chan, Wing C, Vose, Julie M, O'Brien, Susan, Davis, Richard E, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lymphoma, Hematology, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adenine, Antineoplastic Agents, B-Cell Activation Factor Receptor, Biomarkers, Tumor, Cell Line, Tumor, Chemokine CCL3, Chemokine CCL4, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Humans, Lymphoma, Large B-Cell, Diffuse, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Signal Transduction, chemokines, diffuse large B-cell lymphoma, lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironment. We measured CCL3 and CCL4 serum concentrations in 102 patients with newly diagnosed DLBCL by enzyme-linked immunosorbent assay, investigated their prognostic impact and validated our findings in an independent cohort of 51 patient samples. We also tested CCL3 and CCL4 secretion by DLBCL cells, and the influence of BTK inhibitors on the secretion of these chemokines. High CCL3 (≥40 pg/ml) serum concentrations correlated with higher international prognostic index, lactate dehydrogenase and β2 microglobulin, as did CCL4 (≥180 pg/ml) with advanced Ann Arbor stages. High CCL3 levels correlated with significantly shorter progression-free and overall survival. The in vitro studies demonstrated that activated B cell-like, but not germinal centre B cell-like DLBCL cells, secrete high levels of CCL3 and CCL4 after BCR triggering, which was exquisitely sensitive to BCR pathway inhibition. These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL.

Published
2015

19. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy

Author

Yoder, Alison K., Gunther, Jillian R., Milgrom, Sarah A., Mirkovic, Dragan, Nastoupil, Loretta, Neelapu, Sattva, Fanale, Michelle, Fowler, Nathan, Westin, Jason, Lee, Hun Ju, Rodriguez, M.Alma, Iyer, Swaminathan P., Fayad, Luis, Nieto, Yago L., Hosing, Chitra, Ahmed, Sairah, Medeiros, L.Jeffrey, Khoury, Joseph D., Garg, Naveen, Amini, Behrang, Dabaja, Bouthaina S., and Pinnix, Chelsea C.

Published
2019
Full Text
View/download PDF

20. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Author

Dunleavy, Kieron, Fanale, Michelle A, Abramson, Jeremy S, Noy, Ariela, Caimi, Paolo Fabrizio, Pittaluga, Stefania, Parekh, Samir, Lacasce, Ann, Hayslip, John W, Jagadeesh, Deepa, Nagpal, Sunil, Lechowicz, Mary Jo, Gaur, Rakesh, Lucas, Andrea, Melani, Christopher, Roschewski, Mark, Steinberg, Seth M, Jaffe, Elaine S, Kahl, Brad, Friedberg, Jonathan W, Little, Richard F, Bartlett, Nancy L, and Wilson, Wyndham H

Published
2018
Full Text
View/download PDF

22. P1064: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 STUDY

Author

Yasenchak, Chris, primary, Flinn, Ian W., additional, Melear, Jason, additional, Ramchandren, Rod, additional, Friedman, Judah, additional, Burke, John M., additional, Linhares, Yuliya, additional, Gonzales, Paul, additional, Raval, Mihir, additional, Chintapatla, Rangaswamy, additional, Feldman, Tatyana A., additional, Yimer, Habte, additional, Islas-Ohlmayer, Miguel, additional, Dean, Asad, additional, Rana, Vishal, additional, Gandhi, Mitul D., additional, Renshaw, John, additional, Ho, Linda, additional, Fanale, Michelle, additional, Guo, Wenchuan, additional, and Ju Lee, Hun, additional

Published
2023
Full Text
View/download PDF

23. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

Author

Nieto, Yago, Thall, Peter F., Ma, Junsheng, Valdez, Benigno C., Ahmed, Sairah, Anderlini, Paolo, Popat, Uday, Jones, Roy B., Shpall, Elizabeth J., Hosing, Chitra, Qazilbash, Muzaffar, Kebriaei, Partow, Alousi, Amin, Timmons, Melissa, Gulbis, Alison, Myers, Alan, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Milgrom, Sarah, Champlin, Richard, and Andersson, Borje S.

Published
2018
Full Text
View/download PDF

24. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy

Author

Pinnix, Chelsea C., Cella, Laura, Andraos, Therese Y., Ayoub, Zeina, Milgrom, Sarah A., Gunther, Jillian, Thosani, Sonali, Wogan, Christine, Conson, Manuel, D'Avino, Vittoria, Oki, Yasuhiro, Fanale, Michelle, Lee, Hun J., Neelapu, Sattva, Fayad, Luis, Hagemeister, Frederick, Rodriguez, M. Alma, Nastoupil, Loretta J., Nieto, Yago, Qiao, Wei, Pacelli, Roberto, and Dabaja, Bouthaina

Published
2018
Full Text
View/download PDF

25. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma

Author

Milgrom, Sarah A., Pinnix, Chelsea C., Chi, T. Linda, Vu, Thinh H., Gunther, Jillian R., Sheu, Tommy, Fowler, Nathan, Westin, Jason R., Nastoupil, Loretta J., Oki, Yasuhiro, Fayad, Luis E., Neelapu, Sattva, Rodriguez, Maria Alma, Hagemeister, Frederick B., Fanale, Michelle A., Lee, Hun J., Hosing, Chitra, Ahmed, Sairah, Nieto, Yago, Shpall, Elizabeth J., and Dabaja, Bouthaina S.

Published
2018
Full Text
View/download PDF

27. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Author

Akhtari, Mani, Milgrom, Sarah A., Pinnix, Chelsea C., Reddy, Jay P., Dong, Wenli, Smith, Grace L., Mawlawi, Osama, Abou Yehia, Zeinab, Gunther, Jillian, Osborne, Eleanor M., Andraos, Therese Y., Wogan, Christine F., Rohren, Eric, Garg, Naveen, Chuang, Hubert, Khoury, Joseph D., Oki, Yasuhiro, Fanale, Michelle, and Dabaja, Bouthaina S.

Published
2018
Full Text
View/download PDF

30. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Hamadani, Mehdi, Reimer, Peter, Gisselbrecht, Christian, d'Amore, Francesco, Jantunen, Esa, Ishida, Takashi, Bazarbachi, Ali, Foss, Francine, Advani, Ranjana, Fenske, Timothy S., Lazarus, Hillard M., Friedberg, Jonathan W., Aljurf, Mahmoud, Sokol, Lubomir, Tobinai, Kensei, Tse, Eric, Burns, Linda J., Chavez, Julio C., Reddy, Nishitha M., Suzuki, Ritsuro, Ahmed, Sairah, Nademanee, Auayporn, Mohty, Mohamad, Gopal, Ajay K., Fanale, Michelle A., Pro, Barbara, Moskowitz, Alison J., Sureda, Anna, Perales, Miguel Angel, Carpenter, Paul A., and Savani, Bipin N.

Published
2017
Full Text
View/download PDF

33. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

Author

Fanale, Michelle A., Cheah, Chan Yoon, Rich, Amy, Medeiros, L.Jeffrey, Lai, Chao-Ming, Oki, Yasuhiro, Romaguera, Jorge E., Fayad, Luis E., Hagemeister, F.B., Samaniego, Felipe, Rodriguez, Maria A., Neelapu, Sattva S., Lee, Hun J., Nastoupil, Loretta, Fowler, Nathan H., Turturro, Francesco, Westin, Jason R., Wang, Michael L., McLaughlin, Peter, Pinnix, Chelsea C., Milgrom, Sarah A., Dabaja, Bouthaina, Horowitz, Sandra B., and Younes, Anas

Published
2017
Full Text
View/download PDF

35. A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma

Author

Milgrom, Sarah A., Elhalawani, Hesham, Lee, Joonsang, Wang, Qianghu, Mohamed, Abdallah S. R., Dabaja, Bouthaina S., Pinnix, Chelsea C., Gunther, Jillian R., Court, Laurence, Rao, Arvind, Fuller, Clifton D., Akhtari, Mani, Aristophanous, Michalis, Mawlawi, Osama, Chuang, Hubert H., Sulman, Erik P., Lee, Hun J., Hagemeister, Frederick B., Oki, Yasuhiro, Fanale, Michelle, and Smith, Grace L.

Published
2019
Full Text
View/download PDF

40. Supplementary File 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 6 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

45. Supplementary File 1 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 5 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 1, Supplementary Table 2 from Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, primary, Park, Haeseong, primary, Call, S. Greg, primary, Madwani, Kiran, primary, Oki, Yasuhiro, primary, Subbiah, Vivek, primary, Hong, David S., primary, Naing, Aung, primary, Velez-Bravo, Vivianne M., primary, Barnes, Tamara G., primary, Hagemeister, Fredrick B., primary, Falchook, Gerald S., primary, Karp, Daniel D., primary, Wheler, Jennifer J., primary, Piha-Paul, Sarina A., primary, Garrido-Laguna, Ignacio, primary, Shpall, Elizabeth J., primary, Fayad, Luis E., primary, Neelapu, Sattva S., primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Fanale, Michelle A., primary

Published
2023
Full Text
View/download PDF

48. Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study

Author

Parsons, Susan K., primary, Yu, Kristina S., additional, Liu, Nicholas, additional, Kumar, Supriya, additional, Fanale, Michelle A., additional, Holmes, Katie, additional, Flores, Carlos, additional, Surinach, Andy, additional, Flora, Darcy R., additional, and Evens, Andrew M., additional

Published
2023
Full Text
View/download PDF

49. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Author

Westin, Jason, primary, Davis, R. Eric, additional, Feng, Lei, additional, Hagemeister, Fredrick, additional, Steiner, Raphael, additional, Lee, Hun Ju, additional, Fayad, Luis, additional, Nastoupil, Loretta, additional, Ahmed, Sairah, additional, Rodriguez, Alma, additional, Fanale, Michelle, additional, Samaniego, Felipe, additional, Iyer, Swaminathan P., additional, Nair, Ranjit, additional, Oki, Yasuhiro, additional, Fowler, Nathan, additional, Wang, Michael, additional, Ma, Man Chun John, additional, Vega, Francisco, additional, McDonnell, Timothy, additional, Pinnix, Chelsea, additional, Griffith, Donna, additional, Lu, Yang, additional, Tewari, Sanjit, additional, Sun, Ryan, additional, Scott, David W., additional, Flowers, Christopher R., additional, Neelapu, Sattva, additional, and Green, Michael R., additional

Published
2023
Full Text
View/download PDF

50. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Author

Younes, Anas, Santoro, Armando, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M, Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B, Collins, Graham, Savage, Kerry J, Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto, Parker, Susan M, Rodig, Scott, Roemer, Margaretha G M, Ligon, Azra H, and Engert, Andreas

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results